|
[1] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for diagnosis and treatment liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.
|
|
[2]ARVANITI V, D'AMICO G, FEDE G, et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology, 2010, 139 (4) :1246-1256.
|
|
[3]FERNANDEZ J, ACEVEDO J, WIEST R, et al.Bacterial and fungal infections in acute-on-chronic liver failure:Prevalence, characteristics and impact on prognosis[J].Gut, 2017.[Epub ahead of print]
|
|
[4]NING Q.Acute exacerbation of chronic hepatitis B:Basic research and clinical management[M].Huazhong University of Science Technology Press, 2014. (in Chinese) 宁琴.乙型肝炎重症化基础与临床[M].华中科技大学出版社, 2014.
|
|
[5]GODBOLE G, SHANMUGAM N, DHAWAN A, et al.Infectious complications in pediatric acute liver failure[J].J Pediatr Gastroenterol Nutr, 2011, 53 (3) :320-325.
|
|
[6]CHOUDHURY A, KUMAR M, SHARMA BC, et al.Systemic inflammatory response syndrome in acute-on-chronic liver failure:Relevance of'golden window':A prospective study[J].J Gastroenterol Hepatol, 2017, 32 (12) :1989-1997.
|
|
[7]JHA AK, NIJHAWAN S, SUCHISMITA A.Sepsis in acute on chronic liver failure[J].Dig Dis Sci, 2011, 56 (4) :1245-1246.
|
|
[8]SARIN SK, CHOUDHURY A.Acute-on-chronic liver failure[J].Curr Gastroenterol Rep, 2016, 18 (12) :61.
|
|
[9]MANAKKAT VIJAY GK, RYAN JM, ABELES RD, et al.Neutrophil toll-like receptor 9 expression and the systemic inflammatory response in acetaminophen-induced acute liver failure[J].Crit Care Med, 2016, 44 (1) :43-53.
|
|
[10]SARIN SK, KEDARISETTY CK, ABBAS Z, et al.Acute-onchronic liver failure:Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.
|
|
[11]WASMUTH HE, KUNZ D, YAGMUR E, et al.Patients with acute on chronic liver failure display"sepsis-like"immune paralysis[J].J Hepatol, 2005, 42 (2) :195-201.
|
|
[12]BERNSMEIER C, TRIANTAFYLLOU E, BRENIG R, et al.CD14 (+) CD15 (-) HLA-DR (-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure[J].Gut, 2018, 67 (6) :1155-1167.
|
|
[13]SCHLATTMANN P, BRUNKHORST FM.Procalcitonin as a diagnostic marker for sepsis[J].Lancet Infect Dis, 2014, 14 (3) :189.
|
|
[14]VINCENT JL, MORENO R, TAKALA J, et al.The SOFA (Sepsisrelated Organ Failure Assessment) score to describe organ dysfunction/failure.On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine[J].Intensive Care Med, 1996, 22 (7) :707-710.
|
|
[15]MA K, GUO W, HAN M, et al.Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure:Establishment of a novel logistical regression model[J].Hepatol Int, 2012, 6 (4) :735-743.
|
|
[16]WAN YM, LI YH, XU ZY, et al.Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C[J].J Clin Gastroenterol, 2018.[Epub ahead of print]
|
|
[17]GARG H, SARIN SK, KUMAR M, et al.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J].Hepatology, 2011, 53 (3) :774-780.
|
|
[18]WILLIAM M, LEE M, LARSON AM, et al.AASLD position paper:The management of acute liver failure:Update[J].Hepatology, 2011:55.
|
|
[19]JALAN R, FERNANDEZ J, WIEST R, et al.Bacterial infections in cirrhosis:A position statement based on the EASL Special Conference 2013[J].J Hepatol, 2014, 60 (6) :1310-1324.
|
|
[20]VERMA A, AUZINGER G, KANTECKI M, et al.Safety and efficacy of anidulafungin for fungal infection in patients with liver dysfunction or multiorgan failure[J].Open Forum Infect Dis, 2017, 4 (1) :ofw241.
|
|
[21]LIMPER AH, KNOX KS, SAROSI GA, et al.An official American Thoracic Society statement:Treatment of fungal infections in adult pulmonary and critical care patients[J].Am J Respir Crit Care Med, 2011, 183 (1) :96-128.
|
|
[22]GARG V, GARG H, KHAN A, et al.Granulocyte colony-stimulating factor mobilizes CD34 (+) cells and improves survival of patients with acute-on-chronic liver failure[J].Gastroenterology, 2012, 142 (3) :505-512.e1.
|
|
[23]SAHA BK, MAHTAB MA, AKBAR SMF, et al.Therapeutic implications of granulocyte colony stimulating factor in patients with acute-on-chronic liver failure:Increased survival and containment of liver damage[J].Hepatol Int, 2017, 11 (6) :540-546.
|
|
[24]SINGH V, KEISHAM A, BHALLA A, et al.Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis[J].Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[25]DUAN XZ, LIU FF, TONG JJ, et al.Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure[J].World J Gastroenterol, 2013, 19 (7) :1104-1110.
|
|
[26]SUN ZJ, HU JH.Research advances in granulocyte colony-stimulating factor in treatment of liver failure[J].Chin Hepatol, 2014, 19 (10) :787-789. (in Chinese) 孙子健, 胡瑾华.粒细胞集落刺激因子治疗肝功能衰竭机制研究进展[J].肝脏, 2014, 19 (10) :787-789.
|
|
[27]SJOGREN MH.Thymalfasin:An immune system enhancer for the treatment of liver disease[J].J Gastroenterol Hepatol, 2004, 19 (12) :s69-s72.
|
|
[28]NAIR J, KUMAR VHS.Liver failure and conjugated hyperbilirubinemia in a preterm neonate:Role of early IVIG and exchange transfusion[J].AJP Rep, 2018, 8 (2) :e95-e98.
|
|
[29]BERNSMEIER C, SINGANAYAGAM A, PATEL VC, et al.Immunotherapy in the treatment and prevention of infection in acute-onchronic liver failure[J].Immunotherapy, 2015, 7 (6) :641-654.
|
|
[30]ARROYO V, GARCIA-MARTINEZ R, SALVATELLA X.Human serum albumin, systemic inflammation, and cirrhosis[J].JHepatol, 2014, 61 (2) :396-407.
|
|
[31]O'BRIEN AJ, FULLERTON JN, MASSEY KA, et al.Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2[J].Nat Med, 2014, 20 (5) :518-523.
|
|
[32]CHINA L, MAINI A, SKENE SS, et al.Albumin counteracts immune-suppressive effects of lipid mediators in patients with advanced liver disease[J].Clin Gastroenterol Hepatol, 2018, 16 (5) :738-747.e7.
|
|
[33] CHEN Y, JI F, GUO J, et al.Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology[J].Sci Rep, 2016, 6:34055.
|
|
[34]GONG S, LAN T, ZENG L, et al.Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice[J].JHepatol, 2018, 69 (1) :51-59.
|
|
[35]BAJAJ JS, KASSAM Z, FAGAN A, et al.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:Arandomized clinical trial[J].Hepatology, 2017, 66 (6) :1727-1738.
|
|
[36]CRUM-CIANFLONE NF, SULLIVAN E, BALLON-LANDA G.Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization[J].J Clin Microbiol, 2015, 53 (6) :1986-1989.
|
|
[37]FERNANDEZ J, TANDON P, MENSA J, et al.Antibiotic prophylaxis in cirrhosis:Good and bad[J].Hepatology, 2016, 63 (6) :2019-2031.
|
|
[38]WIEST R, KRAG A, GERBES A.Spontaneous bacterial peritonitis:Recent guidelines and beyond[J].Gut, 2012, 61 (2) :297-310.
|
|
[39]CHAVEZ-TAPIA NC, BARRIENTOS-GUTIERREZ T, TELLEZ-AVILA F, et al.Meta-analysis:Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding-an updated Cochrane review[J].Aliment Pharmacol Ther, 2011, 34 (5) :509-518.
|
|
[40]BAJAJ JS, ANANTHAKRISHNAN AN, HAFEEZULLAH M, et al.Clostridium difficile is associated with poor outcomes in patients with cirrhosis:A national and tertiary center perspective[J].Am J Gastroenterol, 2010, 105 (1) :106-113.
|
DownLoad: